NASDAQ:VCNX Vaccinex (VCNX) Stock Price, News & Analysis $1.00 +0.23 (+29.45%) As of 06/5/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock About Vaccinex Stock (NASDAQ:VCNX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Vaccinex alerts:Sign Up Key Stats Today's Range$1.00▼$1.0050-Day Range$0.77▼$1.2852-Week Range$0.31▼$1.50Volume109 shsAverage Volume3,718 shsMarket Capitalization$2.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vaccinex, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders. In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors. Concurrently, the company is conducting a pivotal Phase 2/3 study in early Huntington’s disease, evaluating pepinemab’s ability to slow cognitive and functional decline. Vaccinex’s pipeline also includes preclinical candidates targeting additional indications driven by SEMA4D biology, supported by collaborations with academic institutions and industry partners. Founded in the early 2000s, Vaccinex operates primarily in the United States, where it manages its clinical development, regulatory affairs and manufacturing activities. Under the leadership of President and CEO David Hallal, the company remains focused on advancing its strategic pipeline toward key regulatory milestones and potential commercialization, leveraging partnerships to broaden its research and development capabilities.AI Generated. May Contain Errors. Read More Receive VCNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VCNX Stock News HeadlinesVaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025April 29, 2026 | quiverquant.comQVaccinex Reports 2025 Annual Financial ResultsApril 29, 2026 | globenewswire.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 7 at 1:00 AM | Reagan Gold Group (Ad)Vaccinex Inc.April 10, 2026 | barrons.comVaccinex announces $60M revenue sharing agreement with PDVDecember 23, 2025 | msn.comVaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s DiseaseDecember 23, 2025 | markets.businessinsider.comVaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s TreatmentDecember 23, 2025 | quiverquant.comQVaccinex presents promising cancer treatment data at ASCOMay 29, 2025 | uk.investing.comSee More Headlines VCNX Stock Analysis - Frequently Asked Questions How have VCNX shares performed this year? Vaccinex's stock was trading at $1.0755 at the beginning of the year. Since then, VCNX stock has decreased by 7.0% and is now trading at $1.00. How were Vaccinex's earnings last quarter? Vaccinex, Inc. (NASDAQ:VCNX) released its quarterly earnings results on Monday, November, 8th. The company reported ($35.70) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($60.90) by $25.20. The business had revenue of $0.05 million for the quarter. When did Vaccinex's stock split? Vaccinex's stock reverse split on Tuesday, February 20th 2024.The 1-14 reverse split was announced on Tuesday, February 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Vaccinex IPO? Vaccinex (VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Vaccinex? Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vaccinex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaccinex investors own include Pfizer (PFE), VBI Vaccines (VBIV), OPKO Health (OPK), Plug Power (PLUG), NIO (NIO) and SNDL (SNDL). Company Calendar Last Earnings11/08/2021Today6/07/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VCNX CIK1205922 Webwww.vaccinex.com Phone(585) 271-2700Fax585-271-2765Employees40Year Founded2001Profitability EPS (Trailing Twelve Months)($48.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.25 million Net MarginsN/A Pretax Margin-4,787.89% Return on EquityN/A Return on Assets-383.58% Debt Debt-to-Equity RatioN/A Current Ratio0.77 Quick Ratio0.77 Sales & Book Value Annual Sales$388 thousand Price / Sales6.70 Cash FlowN/A Price / Cash FlowN/A Book Value($2.59) per share Price / Book-0.39Miscellaneous Outstanding Shares2,600,000Free Float1,261,000Market Cap$2.60 million OptionableNo Data Beta1.10 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:VCNX) was last updated on 6/7/2026 by MarketBeat.com Staff. From Our Partners$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccinex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccinex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VCNX Stock Alerts